<!-- ai-dev:event:v2 -->
```yaml
schema: ai-dev/event-v2
event: REVIEW_RESULT
actor_role: reviewer
operator_kind: chatgpt-web
operator_id: "chatgpt-web:app8-l1-authority-review-01"
session_ref: "app8-issue3-successor-review-20261007"
transport_actor: "github:kaicreator-mm"
task: "#3"
sha: "a879ffc081335a2c5c2860dc1f140bbaad54e84f"
status: FAIL
next_state: changes-requested
```

# v0.1 decomposed L1 authority package — context-fresh successor adversarial review

## Terminal

```text
L1_AUTHORITY_PACKAGE_SUCCESSOR_REVIEW = FAIL
REVIEWED_HEAD = a879ffc081335a2c5c2860dc1f140bbaad54e84f
STANDARD = kaicreator-mm/ai-development-standard@7929012f36a2202dcc2edc7a414b8163adc7afbd (4.9.0)
BASELINE_RECHECK_BEFORE_PUBLISH = MATCH
P0 = 0
P1 = 3
P2 = 3
P3 = 0
PRODUCT_FREEZE = NO
L2_READY = NO
E00 = NOT_RUN
E01 = NOT_RUN
E02 = NOT_RUN
E03 = NOT_RUN
NEXT = revise authority package/protocols -> context-fresh successor review
```

This is **not** a Product Freeze review. The FAIL means the current exact package is not yet coherent enough to authorize E00–E03 execution as the preregistered Freeze path.

Independence is context-fresh/self-attested: this reviewer did not author the decomposed package or participate in app8 r1–r5 authoring/review, used a new operator/session identity, and rebuilt the review only from GitHub durable state plus the pinned ADS. No repository/product documents, Issue metadata/state, branch, PR, or code were modified; only ROLE_CLAIMED and this REVIEW_RESULT were written to Issue #3.

## Exact-baseline/currentness check

Immediately before publishing:

- repository HEAD = `a879ffc081335a2c5c2860dc1f140bbaad54e84f`;
- all five authority blobs in Issue #3 match exactly;
- all E00–E03 protocol/result blobs match `PRODUCT_FREEZE.md`;
- Issue #3 had no competing REVIEW_RESULT/terminal;
- `.dev-standard/VERSION` pins ADS 4.9.0 at the exact required revision.

`PRODUCT_FREEZE.md` is aggregation-only and currently consistent.

## A. r5 P0/P1 successor disposition

| r5 finding | successor disposition | reason |
|---|---|---|
| P0-1 — T2 could not falsify the value thesis | **FIXED** | T2/four-arm formulation was removed. E02 now generates treatment evidence blind to ground-truth labels, freezes explicit sensitivity/specificity/incremental-detection/non-inferiority criteria, and FAIL triggers K2/K3. |
| P1-1 — P1 defer path contradicted ADS | **FIXED** | PRD INV-006, L1 Evidence Index and Freeze rule all require open valid P0=0 and P1=0; no P1 defer path remains. |
| P1-2 — CAL/PREV false-positive / estimator ambiguity | **FIXED** | E00 now calibrates sensitivity **and** specificity; E01 is per-tool/unweighted, false-safe-only, has conservative UNKNOWN handling, exact detector-digest reuse, bounded expansion/no optional stopping, blind materiality adjudication and durable same-population FAIL semantics. |
| P1-3 — REFUTED ratchet/lineage underspecified | **FIXED as L1 decomposition** | Exact propagation algebra is no longer claimed solved at L1; INV-002 retains negative-evidence product semantics and Q-L2-005 preserves the architecture problem, including evidence-shopping/false-poisoning constraints. |
| P1-4 — environment member binding underspecified | **FIXED as L1 decomposition** | The PRD retains scoped evidence semantics; host-realization/template-instance mechanics are explicitly moved to Q-L2-002/003 for L2. |
| P1-5 — malicious Provider threat boundary / output trust | **OPEN** | Output trust is restored by INV-007/Q-L2-007, but the product-level threat boundary is still not frozen; Q-L2-001 delegates the **exact threat boundary itself** to L2. |

No r5 P0 remains open. One r5 P1 remains open, and two additional P1 defects are present in the decomposed package.

## B. Current blocking findings

### P1-1 — Product-level security promise is still transferred to L2

**Location / Evidence:** PRD §4 security boundary, §7 invariants, §10 L1→L2 Transfer Test; `L2_QUESTION_REGISTER.md` Q-L2-001.

**Expected:** L1 may defer the enforcement mechanism, but not the product-level security/threat promise. The Transfer Test explicitly forbids transfer when the answer changes the product-level safety promise.

**Actual:** Q-L2-001 asks L2 to decide not only *which mechanism* implements isolation, but also “what exact threat boundary does it support,” including sandbox-escape/kernel-exploit assumptions and privileges. The PRD does not first freeze which malicious/test-aware Provider behaviors are IN/OUT, the minimum isolation promise, or the residual-risk boundary. Therefore L2 is free to change a product promise rather than merely choose an implementation.

This is the unresolved portion of r5 P1-5.

**Required change:** Freeze the product-level threat boundary in L1 (minimum protected behaviors, explicit IN/OUT assumptions such as malicious Provider vs kernel/sandbox escape, secret/output residual-risk policy). Q-L2-001 may then select an architecture that satisfies that already-frozen promise.

### P1-2 — PCL-003 contains an L1 conjunct that no L1 evidence tests

**Location / Evidence:** PRD PCL-003; L1 Evidence Index claim map; E02 protocol; Q-L2-009.

**Expected:** Every normative conjunct of a Product Claim must be falsifiable before Product Freeze, or be removed/narrowed from the claim. A negative L2 answer may not invalidate a Frozen Product Claim.

**Actual:** PCL-003 says executable evidence improves decisions “without unacceptable false denial **or operational cost**.” E02 has criteria for sensitivity, specificity, incremental detection and benign non-inferiority, but **no operational-cost metric or threshold**. Performance/cost is instead delegated to Q-L2-009, which says failure may reposition the product to CI/governance.

Thus the package can mark PCL-003 demonstrated and Freeze without ever testing one of its own conjuncts; a later L2 performance failure can change product positioning.

**Required change:** Either:
1. remove/narrow the operational-cost conjunct from PCL-003 and explicitly make performance a post-Freeze non-blocking architecture/positioning question; or
2. add a preregistered L1 operational-cost criterion/evidence source and make it part of PCL-003’s Gate.

### P1-3 — E02 does not actually isolate Provider-behavior Evidence as the only arm difference

**Location / Evidence:** E02 “Key isolation rule”, Baseline S, Treatment E, Primary PASS criteria.

**Expected:** Because E02 claims causal incremental decision value from Provider-behavior Evidence, S and E must use the same pre-frozen admission/decision procedure; the only treatment difference should be the additional generated evidence.

**Actual:** E02 freezes the same Provider/case, typed invocation surface, enforcement runtime/policy, enforcer configuration and task/policy requirements, and correctly keeps treatment blind to ground-truth labels. But it does **not** freeze one shared admission/decision function or decision-engine digest. The protocol only specifies different *inputs*. Two arm-specific decision procedures can therefore produce the paired decision outputs, allowing measured `E-S` improvement to come from rule/classifier differences rather than Evidence itself.

Blind labels close the prior answer-key defect; they do not close this isolation defect.

**Required change:** Pre-freeze one shared decision/admission procedure (or exact decision-engine digest/rule set) used by both arms, with S receiving only static inputs and E receiving the same inputs plus generated Provider-behavior evidence. Any arm-specific rule change must invalidate the run.

## C. Non-blocking substantive findings

### P2-1 — E02’s paired-CI authority can be frozen too late

The primary Gate depends on paired 95% CI lower bounds, but the exact paired-CI method and analysis script are only required to be frozen “before labels are revealed.” Near a threshold, valid paired methods can yield different bounds. Freeze the exact method/script (or immutable referenced analysis-plan blob) before experimental arm outputs are generated, not merely before label reveal.

### P2-2 — E00 aggregates implementer-known and independent calibration cases without an independent-subset Gate

E00 requires only >=50% of each class to be independently authored/sourced, while PASS is computed over the aggregate. Cases authored by the detector implementer are not meaningfully label-blind to that implementer and can inflate aggregate performance. Report and Gate the independent subset separately, or make the full scored corpus label-blind to the implementer.

### P2-3 — Q-L2-010 is not really an L2 architecture question

“How often valuable non-trivial Providers require deeper-than-thin adaptation” and “what adaptation levels remain economically acceptable” are empirical product/economic questions. They do not currently block the Provider-native v0.1 claim, so they should be a later Product Evidence / roadmap research item (or explicitly non-blocking evidence), not `L2_REQUIRED` architecture authority.

## D. Other attacked targets

- **PRD decomposition:** materially improved; current PRD is product-level and retains falsifiable PCLs, invariants, kill criteria and anti-metrics.
- **L1 Evidence Index:** mostly remains claim→evidence authority rather than redefining product claims.
- **E00:** sensitivity + specificity calibration exists; detector identity is reusable.
- **E01:** primary estimator/direction/UNKNOWN/digest/stopping rules are now coherent and auditable.
- **E02:** treatment evidence is generated blind to ground-truth labels and K2/K3 consequences are explicit; blocking defects are the PCL-003 cost gap and decision-procedure isolation above.
- **E03:** external-participant and concrete pilot-commitment rules are materially adequate.
- **Result authority / What Was NOT Proven:** placeholders are correctly NOT_RUN and bind exact protocol blobs.
- **Migration:** output trust, kill criteria and anti-metrics are restored; major r5/r4 semantics are generally accounted for. Hard-case adaptation is preserved but misclassified by P2-3.
- **Freeze manifest:** aggregation-only, exact-blob-consistent, and does not claim Product Freeze.

## Gate consequence

Issue #3 requires:

```text
PASS =>
open valid P0 = 0
open valid P1 = 0
AND no authority-boundary defect that makes E00–E03 ambiguous/non-auditable
```

Current result:

```text
open valid P0 = 0
open valid P1 = 3
=> PASS condition not met
=> L1_AUTHORITY_PACKAGE_SUCCESSOR_REVIEW = FAIL
```

Do not execute E00–E03 as the authoritative Product-Freeze evidence sequence under this exact package. Revise the three P1s, preserve the exact migration/accounting chain, then run a new context-fresh successor review on the successor exact baseline.